Abstract Library

#4574 Long-acting somatostatin analogue injections for treating gastroenteropancreatic neuroendocrine tumours (GEP-NETs) and acromegaly: BackSOM – A patient preference study

Introduction: Long-acting somatostatin analogues, lanreotide and octreotide, are indicated for first-line treatment of GEP-NETs and acromegaly. Lanreotide was approved in 2007 in Europe, and is supplied as a prefilled, ready-to-use syringe (LAN-PF). In 2021, a generic form of lanreotide was released and supplied in a syringe requiring assembly (LAN-RA). To ensure patient compliance with treatment, it is important to understand their injection experiences.

Conference:

Presenting Author: Hernando Cubero J

Authors: Rodien-Louw C, Simo-Servat A, Dubois M, Sheppard J, McDonnell M,

Keywords: gastroenteropancreatic neuroendocrine tumour, GEP-NET, acromegaly, lanreotide, LA-SSA, somatostatin, patient preference,

#4155 [177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomised NETTER-2 study

Introduction: There is no universally accepted first line (1L) therapy for higher grade, well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Conference:

Presenting Author: de Herder W

Authors: de Herder W, Halperin D, Myrehaug S, Herrmann K, Pavel M,

Keywords: [177Lu]Lu-DOTA-TATE, Lutathera, Gastroenteropancreatic Neuroendocrine Tumor, NETTER-2,

#4152 Valvular surgery in carcinoid heart disease – Indications and outcome

Introduction: Neuroendocrine tumors (NET) can release biogenic amines that can induce a fibrotic process in the heart valves known as carcinoid heart disease (CHD). Valvular replacement surgery is the standard of care, but such interventions are associated with significant morbidity and valid criteria for both selecting patients (pts) and timing of surgery are limited.

Conference:

Presenting Author:

Authors: Sponheim J, Beitnes J, Dahle G, Åvitsland T, Thiis-Evensen E,

Keywords: carcinoid heart disease, valvular surgery, prognostic factors,

#3815 Real-world observational study of somatostatin analogues and rescue medication use for neuroendocrine tumors in Canada

Introduction: Both octreotide long-acting release (OCT-LAR) and lanreotide autogel (LAN-ATG) are available in Canada for the management of neuroendocrine tumors (NETs). Patients can switch between SSAs due to effectiveness, adverse events (AEs), preference or reimbursement. For patients with functional disease, short acting SSAs can be used concomitantly as rescue medication to improve symptom control.

Conference:

Presenting Author:

Authors: Rayson D, Troesch M, Laforty C, Badin M, Liovas A,

Keywords: Neuroendocrine tumor, Somatostatin analogues, Lanreotide, Octreotide, SSA switch,

#3744 Germline whole-exome sequencing of patients with neuroendocrine neoplasms reveals pathogenic or likely pathogenic variants in a large subset of patients

Introduction: The germline predisposition to neuroendocrine neoplasms (NEN) is not-well understood beyond genetic syndromes associated with MEN1 loss.

Conference:

Presenting Author: Sukrithan V

Authors: Sukrithan V, Boateng I, Jain P, Liyanarachchi S, Buss J,

Keywords: whole exome sequencing, germline, population, mutyh, pkd1, atp4a, pah,